Literature DB >> 2354716

Characterization of dihydrofolate reductase of Pneumocystis carinii and Toxoplasma gondii.

J A Kovacs1, C J Allegra, H Masur.   

Abstract

Pneumocystis carinii and Toxoplasma gondii are opportunistic pathogens of immunosuppressed patients that are susceptible to therapy with inhibitors of dihydrofolate reductase (DHFR). The DHFR of these two organisms was characterized to facilitate the identification of more selective inhibitors. Similar to all reported protozoa, T. gondii has a bifunctional enzyme, of 120,000 Da, that possesses both DHFR and thymidylate synthase (TS) activity. Unexpectedly, P. carinii DHFR activity was present on a small molecule, of 26,000 Da. T. gondii DHFR and TS activity coeluted during affinity chromatography using a methotrexate-Sepharose column, whereas P. carinii DHFR and TS activity could be separated by affinity chromatography using the same column. P. carinii DHFR could be easily distinguished from rat DHFR, which is similar in size, by the differences in Km for dihydrofolate (P. carinii, 17.6 +/- 3.9 microM; rat, 4.0 +/- 2.2 microM). Since all protozoa reported have a large molecular weight, bifunctional DHFR, these studies support the classification of P. carinii as a fungus. These studies also provide a basis for the development of more effective therapeutic agents for these pathogens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2354716     DOI: 10.1016/0014-4894(90)90008-z

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  6 in total

1.  Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase.

Authors:  L C Chio; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

2.  Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase.

Authors:  L Ma; J A Kovacs
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

3.  Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs.

Authors:  M C Broughton; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

4.  Fungus-specific translation elongation factor 3 gene present in Pneumocystis carinii.

Authors:  M F Ypma-Wong; W A Fonzi; P S Sypherd
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

5.  Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.

Authors:  M S Bartlett; M Shaw; P Navaran; J W Smith; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

6.  A molecular model of the folate binding site of Pneumocystis carinii dihydrofolate reductase.

Authors:  W M Southerland
Journal:  J Comput Aided Mol Des       Date:  1994-04       Impact factor: 3.686

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.